Topic: How To Invest

Power Growth Investor Hotline – Friday, October 14, 2022

Article Excerpt

MERCK & CO. INC., $92.18, is a buy. The drugmaker (symbol MRK on New York) is a pharmaceutical leader in oncology, acute-care and animal health drugs as well as vaccines. Merck has now exercised an option to jointly develop and potentially sell an mRNA-based cancer vaccine along with Moderna (symbol MRNA on Nasdaq). The vaccine, mRNA-4157, is being tested in conjunction with Merck’s blockbuster cancer immunotherapy Keytruda, in a mid-stage trial. Data on the vaccine is expected in the fourth quarter of this year. Merck will pay $250 million to exercise the option, as agreed under a 2016 deal. The vaccine is designed to generate T-cells, a key part of the body’s immune response, based on the mutational signature of a patient’s tumor. Merck is a buy. Merck & Co. recent coverage: Hotline for September 30, 2022 Hotline for September 23, 2022 AMERIGO RESOURCES LTD., $0.98, is a buy for aggressive investors. The company, symbol ARG on Toronto, processes copper and molybdenum from the waste rock…